RNA — Atrium Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2093101 ·
Last close
$6.48
Market Cap
$139.78M
52W High
$16.77
52W Low
$6.36
ADV30
234,797
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 15,321,000 | — | -6,629,000 | -4,266,000 | 263,985,000 | 44,565,000 | 58,967,000 |
| Jun 2026 | 3,004,000 | — | -22,618,000 | -20,186,000 | 280,512,000 | 72,334,000 | 65,936,000 |
| Mar 2026 | 19,635,000 | — | -17,280,000 | -16,633,000 | 292,360,000 | 267,849,000 | 58,256,000 |
| Dec 2025 | 859,000 | — | -48,035,000 | -48,069,000 | 278,353,000 | 270,000,000 | 71,066,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,188,000
Investing CF
$-194,864,000
Financing CF
$320,803,000
CapEx
$-3,313,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.34
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-8,058,000
Inventory
—
Receivables
$15,000,000
ST Investments
$191,566,000
EBIT TTM
$-96,396,000
Pretax Income TTM
$-93,317,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,819,000
EBITDA
$-74,661,000
Free Cash Flow
$-60,449,124
Enterprise Value
$-69,392,984
Total Cash
$232,074,000
Total Debt
$679,000
Shares Out
21,571,507
Trailing EPS
$-5.22
Book Value
$12.50
ROE
-95.0%
ROA
-34.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 18,618,000 | -76,814,000 | -76,684,000 | 278,353,000 | 71,066,000 | 207,287,000 | -41,129,000 |
| Dec 2024 | 10,897,000 | -13,218,000 | -25,122,000 | 7,186,000 | 68,294,000 | -61,108,000 | -22,553,000 |
| Dec 2023 | 9,764,000 | -6,386,000 | -6,385,000 | 10,293,000 | 80,912,000 | -70,619,000 | 56,390,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$280,512,000
Forward EPS
$-5.96
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALXO | ALX ONCOLOGY HOLDINGS INC | $138.97M | $1.00 | — |
| SION | Sionna Therapeutics, Inc. | $138.87M | $3.07 | — |
| MENS | Jyong Biotech Ltd. | $133.62M | $1.80 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $146.42M | $1.49 | — |
| VRXA | Veraxa Biotech AG - Post de-SPAC | $147.06M | $1.04 | — |
News headlines (Yahoo Finance, 1h cache)
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-12 21:10 · Yahoo
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
2026-11-02 11:30 · Yahoo
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
2026-10-27 10:30 · Yahoo
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-20 21:23 · Yahoo
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
2026-10-20 12:09 · Yahoo
Atrium Therapeutics Announces $50 Million Private Placement
2026-10-08 10:30 · Yahoo
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
2026-09-06 10:44 · Yahoo
Atrium Therapeutics to Participate in Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-13 20:44 · Yahoo
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
2026-05-28 10:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.